Carisma Therapeutics Inc.

Please note: The information displayed on this page might be outdated.
Carisma Therapeutics Inc.: Developer of cell therapies intended to treat solid tumors by re-engineering macrophages. The company's therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment, enabling solid tumor patients to receive strong cellular immunotherapy and cancer treatments.
Based in...
US - Middle Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
3025 Market Street, Ste 140
Philadelphia, PA 19104
United States

Company Participants at Fall Private Company Showcase 2020

Steven Kelly
Carisma Therapeutics Inc., CEO
Steven Kelly joined Carisma Therapeutics in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen. Steve holds a BS from the University of Oregon and an MBA from Cornell University.

Upcoming Company Event Participation